Alexander Miller, MD, FAAD interviewed by Brad P. Glick, DO, MPH, FAAD

Stan Miller, MD, FAAD interviewed by Robert Smith, MD, FAAD

For more information on the ABD’s Continuing Certification Program changes, visit https://www.abderm.org/public/perspectives/the-bottom-line-continuing-certification-changes-in-2026.

Pooja R. Shah, MD, FAAD interviewed by Carlos Garcia, MD, FAAD commentary by Lauryn Reid, MD with Jules Lipoff, MD, FAAD (ed.)

Vulvar neoplasms occupy a delicate space where clinical skill meets sensitivity. Listen as Pooja R. Shah, MD, FAAD and Carlos Garcia, MD, FAAD consider how careful assessment and communication strengthen patient trust and care.

View episode transcript

Alina Bridges, MD, FAAD interviewed by Ryan Hick, MD, FAAD

The AAD Practice Management Center has multiple resources on lab management and CLIA at https://www.aad.org/member/practice/compliance/clia

Joel Gelfand, MD, MSCE, FAAD interviewed by Sanna Ronkainen, MD, FAAD

This episode has been sponsored by Johnson & Johnson.

View episode transcript

Milad Eshaq, MD, FAAD interviewed by Olayemi Sokumbi, MD, FAAD

Zelma Chiesa Fuxench, MD, MSCE, FAAD interviewed by Carmen Castilla, MD, FAAD

This episode has been supported by an independent medical education grant from Pfizer.

View episode transcript

interviewed by Charles Dunn, MD, FAAD

Are you curious about the hottest trending topics in dermatology? In this latest episode of “DiD You Know?,” Dr. Charles Dunn discusses The North American Contact Dermatitis Group’s updated guidelines for patch testing patients on immunomodulatory medications. For more information, visit the September “What’s Hot” column of DermWorld at https://www.aad.org/dw/monthly/2025/september/whats-hot-september-2025.

Lily Park, DO, FAAD interviewed by Brad P. Glick, DO, MPH, FAAD

N/A interviewed by Mona Sadeghpour, MD, FAAD

Are you curious about the hottest trending topics in dermatology? In this latest episode of “DiD You Know?,” Dr. Mona Sadeghpour reviews the novel use of IL-5 inhibitors as a steroid-sparing therapy for drug-induced hypersensitivity syndrome (DIHS), previously knowns as drug reaction with eosinophilia and systemic symptoms (DRESS). For more information, visit the August “What’s Hot” column of DermWorld at https://www.aad.org/dw/monthly/2025/august/whats-hot-august-2025.